June 25, 2020 / 5:08 AM / 7 days ago

BRIEF-Kiadis Announces First Patient Enrolled In Clinical Study As Part Of Its K-Nk003 Program

June 25 (Reuters) - Kiadis Pharma NV:

* KIADIS ANNOUNCES FIRST PATIENT ENROLLED IN CLINICAL STUDY CONDUCTED AT THE OHIO STATE UNIVERSITY IN R/R AML WITH OFF-THE-SHELF K-NK CELLS FROM UNIVERSAL DONORS AS PART OF ITS K-NK003 PROGRAM

* KIADIS PHARMA NV - GOAL OF THIS STUDY IS TO ESTABLISH SAFETY OF NK CELL THERAPY FOR INDUCTION OF REMISSION IN PATIENTS WITH R/R AML OR MDS AND TO DETERMINE OPTIMAL DOSING AND OVERALL RESPONSE RATE

* KIADIS PHARMA NV - PHASE I STUDY, NCT04220684, WILL EVALUATE NK CELL PRODUCT IN UP TO 56 PATIENTS, AGES 18 - 80 WHO HAVE PRIMARY REFRACTORY AML, RELAPSED AML, OR MYELODYSPLASTIC SYNDROMES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below